Osteoporosis

Obstetrics and Gynecology

Volumn 104, Issue 4 SUPPL., 2004, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; ESTROGEN THERAPY; FEMALE; HUMAN; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS;

EID: 16544392866     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/01.AOG.0000138799.78545.14     Document Type: Article

References (63)

1. Looker AC, Orwoll ES, Johnston CC Jr, Lindsay RL, Wahner HW, Dunn WL, et al Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res 1997; 12: 1761-8. (Level II-3) (Pubitemid 27500187)
2. National Osteoporosis Foundation. Physician's guide to prevention and treatment of osteoporosis. Washington, DC: NOF; 2003. (Level III)
3. National Institutes of Health. Osteoporosis prevention, diagnosis, and therapy. NIH Consensus Statement 2000; 17: 1-45. Available at: http://consensus.nih.gov/cons/111/111-statement.pdf. Retrieved July 21, 2004. (Level III)
4. Riggs BL, Melton LJ 3rd. The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 1995; 17: 505S-11S. (Level III)
5. Melton LJ 3rd, O'Fallon WM, Riggs BL. Secular trends in the incidence of hip fractures. Calcif Tissue Int 1987; 41: 57-64. (Level II-3)
6. Magaziner J, Simonsick EM, Kashner T.M., Hebel JR, Kenzora JE Predictors of functional recovery one year following hospital discharge for hip fracture: a prospective study. J Gerontol 1990; 45: M101-7. (Level II-2) (Pubitemid 20171157)
7. Gallagher JC, Melton LJ, Riggs B.L., Bergstrath E. Epidemiology of fractures of the proximal femur in Rochester, Minnesota. Clin Orthop 1980; 150: 163-71. (Level II-3) (Pubitemid 10039047)
8. Cook DJ, Guyatt GH, Adachi J.D., Clifton J., Griffith LE, Epstein RS, et al. Quality of life issues in women with vertebral fractures due to osteoporosis. Arthritis Rheum 1993; 36: 750-6. (Level II-3) (Pubitemid 23175615)
9. Hedlund LR, Gallagher JC The effect of age and menopause on bone mineral density of the proximal femur. J Bone Miner Res 1989; 4: 639-42. (Level II-3) (Pubitemid 19224564)
10. Genant HK, Cann CE, Ettinger B, Gordan GS Quantitative computed tomography of vertebral spongiosa: a sensitive method for detecting early bone loss after oophorec-tomy. Ann Intern Med 1982; 97: 699-705. (Level I) (Pubitemid 13251641)
11. Pouilles JM, Tremollieres F, Bonneu M., Ribot C. Influence of early age at menopause on vertebral bone mass. J Bone Miner Res 1994; 9: 311-5. (Level II-2) (Pubitemid 24080567)
12. Coulam CB, Adamson SC, Annegers JF Incidence of premature ovarian failure. Obstet Gynecol 1986; 67: 604-6. (Level II-3) (Pubitemid 16116286)
13. Luborsky JL, Meyer P, Sowers M.F., Gold EB, Santoro N. Premature menopause in a multi-ethnic population study of the menopause transition. Hum Reprod 2003; 18: 199-206. (Level II-3) (Pubitemid 36138877)
14. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994; 843: 1-129. (Level III)
15. Siris ES, Miller PD, Barrett-Connor E, Faulkner K.G., Wehren LE, Abbott TA, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 2001; 286: 2815-22. (Level II-2) (Pubitemid 33126923)
16. Cummings SR, Black DM, Nevitt M.C., Browner W., Cauley J, Ensrud K, et al Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet 1993; 341: 72-5. (Level II-3) (Pubitemid 23028113)
17. Hui SL, Slemenda CW, Johnston CC Jr. Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 1988; 81: 1804-9. (Level II-3)
18. Kanis JA, Black D, Cooper C., Dargent P, Dawson-Hughes B, De Laet C, et al. A new approach to the development of assessment guidelines for osteoporosis. International Osteoporosis Foundation. National Osteoporosis Foundation. Osteoporos Int 2002; 13: 527-36. (Level III) (Pubitemid 34790624)
19. Wells G, Tugwell P, Shea B., Guyatt G, Peterson J, Zytaruk N, et al. Meta-analyses of therapies for postmeno-pausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev 2002; 23: 529-39. (Meta-analysis) (Pubitemid 34925647)
20. Delmas PD, Pornel B, Felsenberg D., Garnero P, Hardy P, Pilate C., et al. A dose-ranging trial of a matrix transdermal 17beta-estradiol for the prevention of bone loss in early postmenopausal women. International Study Group. Bone 1999; 24: 517-23. (Level I) (Pubitemid 29234142)
21. Cooper C, Stakkestad JA, Radowicki S, Hardy P., Pilate C, Dain MP, et al Matrix delivery transdermal 17beta-estra-diol for the prevention of bone loss in postmenopausal women. The International Study Group. Osteoporos Int 1999; 9: 358-66. (Level I) (Pubitemid 29216771)
22. Delmas PD, Confavreux E, Garnero P., Fardellone P, de Vernejoul MC, Cormier C, et al. A combination of low doses of 17 beta-estradiol and norethisterone acetate prevents bone loss and normalizes bone turnover in post-menopausal women. Osteoporos Int 2000; 11: 177-87. (Level I) (Pubitemid 30168805)
23. Bjarnason NH, Byrjalsen I, Hassager C., Haarbo J, Christiansen C. Low doses of estradiol in combination with gestodene to prevent early postmenopausal bone loss. Am J Obstet Gynecol 2000; 183: 550-60. (Level I)
24. McKeever C, McIlwain H, Greenwald M., Gupta N, Jayawardene S, Huels G., et al. An estradiol matrix transdermal system for the prevention of postmenopausal bone loss. Clin Ther 2000; 22: 845-57. (Level I) (Pubitemid 30625917)
25. Lees B, Stevenson JC The prevention of osteoporosis using sequential low-dose hormone replacement therapy with estradiol-17 beta and dydrogesterone. Osteoporos Int 2001; 12: 251-8. (Level I) (Pubitemid 34912730)
26. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 2002; 287: 2668-76. (Level I) (Pubitemid 34533545)
27. Weiss SR, Ellman H, Dolker M. A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss. Transdermal Estradiol Investigator Group. Obstet Gynecol 1999; 94: 330-6. (Level II-1) (Pubitemid 29393064)
28. Notelovitz M, John VA, Good WR Effectiveness of Alora estradiol matrix transdermal delivery system in improving lumbar bone mineral density in healthy, postmenopausal women. Menopause 2002; 9: 343-53. (Level I) (Pubitemid 36701894)
29. Arrenbrecht S, Boermans AJ Effects of transdermal estra-diol delivered by a matrix patch on bone density in hysterectomized, postmenopausal women: a 2-year placebo-controlled trial. Osteoporos Int 2002; 13: 176-83. (Level I) (Pubitemid 34241038)
30. Rubinacci A, Peruzzi E, Modena A.B., Zanardi E., Andrei B, De Leo V, et al. Effect of low-dose transdermal E2/NETA on the reduction of postmenopausal bone loss in women. Menopause 2003; 10: 241-9. (Level I) (Pubitemid 36706310)
31. Gallagher JC, Fowler SE, Detter J.R., Sherman SS Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. J Clin Endocrinol Metab 2001; 86: 3618-28. (Level I) (Pubitemid 32755952)
32. Bone HG, Greenspan SL, McKeever C, Bell N., Davidson M, Downs RW, et al Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab 2000; 85: 720-6. (Level I) (Pubitemid 32273660)
33. Recker RR, Davies KM, Dowd R.M., Heaney RP The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women: a randomized, controlled trial. Ann Intern Med 1999; 130: 897-904. (Level I) (Pubitemid 29239584)
34. Prestwood KM, Kenny AM, Kleppinger A, Kulldorff M. Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial. JAMA 2003; 290: 1042-8. (Level I) (Pubitemid 37430444)
35. Cauley JA, Robbins J, Chen Z., Cummings SR, Jackson RD, LaCroix AZ, et al Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003; 290: 1729-38. (Level I) (Pubitemid 37430623)
36. Anderson GL, Limacher M, Assaf A.R., Bassford T., Beresford SA, Black H, et al Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. The Women's Health Initiative Steering Committee. JAMA 2004; 291: 1701-12. (Level I) (Pubitemid 38489892)
37. Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 2001; 285: 2891-7. (Level I) (Pubitemid 32537354)
38. Komulainen MH, Kroger H, Tuppurainen M.T., Heikkinen AM, Alhava E, Honkanen R., et al. HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women; a 5 year randomized trial. Maturitas 1998; 31: 45-54. (Level I) (Pubitemid 29050890)
39. Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomised trials. BMC Musculoskelet Disord 2001; 2: 7.(Meta-analysis)
40. Mosekilde L, Beck-Nielsen H, Sorensen O.H., Nielsen SP, Charles P, Vestergaard P, et al Hormonal replacement therapy reduces forearm fracture incidence in recent post-menopausal women: results of the Danish Osteoporosis Prevention Study. Maturitas 2000; 36: 181-93. (Level II-2)
41. Banks E, Beral V, Reeves G., Balkwill A, Barnes I. Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women. Million Women Study Collaborators. JAMA 2004; 291: 2212-20. (Level II-2) (Pubitemid 38608170)
42. Kiel DP, Felson DT, Anderson J.J., Wilson PW, Moskowitz MA Hip fracture and the use of estrogens in postmeno-pausal women. The Framingham Study. N Engl J Med 1987; 317: 1169-74. (Level II-2) (Pubitemid 17150327)
43. Naessen T, Persson I, Adami H.O., Bergstrom R., Bergkvist L. Hormone replacement therapy and the risk for first hip fracture: a prospective, population-based cohort study. Ann Intern Med 1990; 113: 95-103. (Level II-2) (Pubitemid 20218626)
44. Grodstein F, Stampfer MJ, Falkeborn M, Naessen T., Persson I. Postmenopausal hormone therapy and risk of cardiovascular disease and hip fracture in a cohort of Swedish women. Epidemiology 1999; 10: 476-80. (Level II-2) (Pubitemid 29398901)
45. Cauley JA, Seeley DG, Ensrud K, Ettinger B., Black D, Cummings SR Estrogen replacement therapy and fractures in older women: study of Osteoporotic Fractures Research Group. Ann Intern Med 1995; 122: 9-16. (Level II-2)
46. Maxim P, Ettinger B, Spitalny GM Fracture protection provided by long-term estrogen treatment. Osteoporos Int 1995; 5: 23-9. (Level II-2)
47. Nieves JW, Komar L, Cosman F., Lindsay R. Calcium potentiates the effect of estrogen and calcitonin on bone mass: review and analysis. Am JClin Nutr 1998; 67: 18-24. (Level III) (Pubitemid 28037620)
48. Greenspan SL, Resnick NM, Parker RA Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. JAMA 2003; 289: 2525-33. (Level I) (Pubitemid 37430154)
49. Harris ST, Eriksen EF, Davidson M, Ettinger M.P., Moffett AH Jr, Baylink DJ, et al. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 2001; 86: 1890-7. (Level I) (Pubitemid 32472892)
50. Evio S, Tiitinen A, Laitinen K., Ylikorkala O, Valimaki MJ Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis. J Clin Endocrinol Metab 2004; 89: 626-31. (Level I) (Pubitemid 38269869)
51. Gallagher JC, Rapuri PB, Haynatzki G, Detter JR Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. J Clin Endocrinol Metab 2002; 87: 4914-23. (Level I) (Pubitemid 35316325)
52. Greenspan SL, Emkey RD, Bone H.G., Weiss SR, Bell NH, Downs RW, et al Significant differential effects of alendro-nate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002; 137: 875-83. (Level I) (Pubitemid 35416623)
53. Greendale GA, Espeland M, Slone S., Marcus R, Barrett-Connor E. Bone mass response to discontinuation of longterm hormone replacement therapy: results from the Post-menopausal Estrogen/Progestin Interventions (PEPI) Safety Follow-up Study. Arch Intern Med 2002; 162: 665-72. (Level I) (Pubitemid 34226393)
54. Tremollieres FA, Pouilles JM, Ribot C. Withdrawal of hormone replacement therapy is associated with significant vertebral bone loss in postmenopausal women. Osteo-poros Int 2001; 12: 385-90. (Level II-2) (Pubitemid 32606463)
55. Lindsay R, Hart DM, Forrest C, Baird C. Prevention of spinal osteoporosis in oophorectomized women. Lancet 1980; 2: 1151-4. (Level II-2) (Pubitemid 11240800)
56. Michaelsson K, Baron JA, Farahmand B.Y., Johnell O., Magnusson C, Persson PG, et al Hormone replacement therapy and risk of hip fracture: population based case-control study. The Swedish Hip Fracture Study Group. BMJ 1998; 316: 1858-63. (Level II-2) (Pubitemid 28276930)
57. Yates J, Barrett-Connor E, Barlas S., Chen YT, Miller PD, Siris ES Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment. Obstet Gynecol 2004; 103: 440-6. (Level II-2) (Pubitemid 40459055)
58. Johnston CC J.r., Bjarnason NH, Cohen F.J., Shah A., Lindsay R, Mitlak BH, et al Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med 2000; 160: 3444-50. (Level I)
59. Delmas PD, Ensrud KE, Adachi J.D., Harper KD, Sarkar S, Gennari C, et al Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation Investigators. J Clin Endocrinol Metab 2002; 87: 3609-17. (Level I) (Pubitemid 34879503)
60. Cranney A, Wells G, Willan A., Griffith L, Zytaruk N, Robinson V., et al. Meta-analyses of therapies for postmeno-pausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Endocr Rev 2002; 23: 508-16. (Meta-analysis)
61. Bone HG, Hosking D, Devogelaer J.P., Tucci JR, Emkey RD, Tonino RP, et al Ten years' experience with alendro-nate for osteoporosis in postmenopausal women. Alendro-nate Phase II Osteoporosis Treatment Study Group. N Engl J Med 2004; 350: 1189-99. (Level I) (Pubitemid 38339363)
62. Cranney A, Tugwell P, Adachi J., Weaver B, Zytaruk N, Papaioannou A., et al. Meta-analyses of therapies for post-menopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Endocr Rev 2002; 23: 517-23. (Meta-analysis)
63. Recker RR, Weinstein RS, Chesnut CH 3rd, Schimmer RC, Mahoney P, Hughes C, et al. Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. Osteoporos Int 2004; 15: 231-7. (Level I) (Pubitemid 38391539)